The World Health Organization’s (WHO) list of priority pathogens has been published!
Just a few weeks ago, the World Health Organization published the “Bacterial Priority Pathogens List 2024”. This highly significant document for the microbial control sector identifies the key areas on which companies like HIFAS Biologics must focus our efforts to fight resistant bacteria and protect global public health.
This new version of the list places special emphasis on the three following pathogens:
Gram-negative pathogens: They remain a critical priority due to their high level of resistance and their significant impact on public health. These pathogens include bacteria such as Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
Rifampicin-Resistant Tuberculosis (RR-TB): Recognized as a critical antimicrobial resistance (AMR) pathogen, it underscores the urgent need for new drugs and diagnostics for its effective control.
Methicillin-resistant Staphylococcus aureus (MRSA): Remains a high priority due to its prevalence and significant resistance. This pathogen is a leading cause of nosocomial and community-acquired infections.
On the other hand, the WHO report also highlights the importance of innovation in research and development (R&D) for the creation of new medicines. The implementation of effective public health actions is essential to address these emerging challenges. Microbial resistance is a dynamic problem that requires urgent innovative solutions and global collaboration.
At Hifas Biologics, we are strongly committed to this global cause. We dedicate all our efforts to combat microbial resistance through the development of fungal-based antibiotics. We strongly believe that mycology research can provide novel and effective solutions in the fight against the priority pathogens identified by the WHO.
May this WHO report inspire new actions and collaborations that complement our work! Together, we can make a difference in global health and tackle antimicrobial resistance with determination and creativity.